Company News for May 27, 2020

Zacks Equity Research Published on May 27, 2020

Shares of Evofem Biosciences, Inc. surged 16% after the clinical-stage biopharmaceutical company disclosed that the FDA had approved its birth control gel Phexxi.
Shares of Benefitfocus, Inc. soared 15.1% after the provider of cloud-based benefits management platform reported $80 million investment by BuildGroup LLC.
Shares of Sorrento Therapeutics, Inc. (SRNE - Free Report) rose 3.9% after the clinical stage biopharma company received FDA IND clearance to initiate Phase I clinical trial of its CD38 antibody-drug conjugate (ADC) STI-6129.
Shares of Cellectar Biosciences, Inc. (CLRB - Free Report) gained 7.1% after it received FDA fast track designation for CLR 131 in Lymphoplasmacytic Lymphoma and Waldenstrom's Macroglobulinemia.

Zacks Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.

This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.